How many insider trades does FilingIQ track for NCNA?

FilingIQ tracks 3 Form 4 insider transactions for NCNA (NuCana plc), covering filings from Apr 15, 2026 onwards. 3 of those were filed in the last 90 days.

Are NCNA insiders net buyers or net sellers?

Across the full Form 4 history for NCNA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NCNA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NCNA in?

NuCana plc (NCNA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.86M.

NCNA insider trading

NasdaqCM Healthcare

NuCana plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$8.86M

About NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Company website: www.nucana.com

NCNA insider activity at a glance

FilingIQ has scored 3 insider transactions for NCNA since Apr 15, 2026. The most recent filing in our index is dated Jun 19, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live NCNA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,196

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

NTRA 133

Natera, Inc.

Frequently asked

How many insider trades does FilingIQ track for NCNA?: FilingIQ tracks 3 Form 4 insider transactions for NCNA (NuCana plc), covering filings from Apr 15, 2026 onwards. 3 of those were filed in the last 90 days.
Are NCNA insiders net buyers or net sellers?: Across the full Form 4 history for NCNA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NCNA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NCNA in?: NuCana plc (NCNA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.86M.

Methodology & sources

Every NCNA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.